Serplulimab is the UK’s first licensed anti-PD-1 monoclonal antibody for this aggressive form of lung cancer. It is indicated for adults with untreated ES-SCLC, where the disease has spread ...

UK MHRA approves Accord Healthcare’s anti-PD-1 monoclonal antibody, serplulimab to treat aggressive form of SCLC: United Kingdom Monday, June 23, 2025, 09:00 Hrs [IST] The Medic ...

UK MHRA approves Accord Healthcare’s anti-PD-1 monoclonal antibody, serplulimab to treat aggressive form of SCLC ... SCLC is a fast-growing cancer that typically develops in the airways of the lungs.

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Accord Healthcare’s Henlius-partnered Hetronifly ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hetronifly (serplulimab) to treat adults ...

ES-SCLC is a form of lung cancer accounting for one in eight lung cancer cases in the UK. It is an aggressive disease that progresses rapidly, with a significant negative impact on the quality of ...

Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in obesity. See why AMGN stock is a buy.

So now we live in a time when Americans in power ignore the Constitution and curtail freedom of speech, freedom of assembly ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to take on the dominance of MSD’s Keytruda (pembrolizumab) in solid tumour ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B for the German biotech.